Reported 3 days ago
Eli Lilly and Company is set to release its Q2 earnings for 2025 on August 7, with analysts predicting a profit of $5.55 per share, a significant increase from the previous year's $3.92. The company, known for its advancements in pharmaceuticals, has seen mixed results in the past and recently adjusted its fiscal 2025 earnings guidance downward. Nonetheless, Wall Street remains optimistic, rating the stock as a 'Strong Buy' with a target price suggesting a notable upside.
Source: YAHOO